Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells

P. Mlejnek, O. Novak, P. Dolezel

. 2011 ; 83 (5) : 1466-71.

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NR9482 MZ0 CEP Register

Multidrug resistance (MDR) is often associated with overexpression of the P-glycoprotein (P-gp, ABCB1). It was demonstrated that the P-gp mediated efflux decreases the drug concentration in cancer cells which results in the failure of chemotherapy. However, the MDR phenotype in cancer cells obviously involves various mechanisms. Therefore, if we want to estimate a contribution of the P-gp expression to the MDR phenotype, a clear quantitative relationship between the intracellular drug level and cell sensitivity must be established. To achieve this goal, a sensitive and non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite N-desmethyl imatinib (CGP 74588) has been developed. The assay is based on an optimised extraction of cells with 4% formic acid after their separation from the growth medium by centrifugation through a layer of silicone oil. Cell extracts are subsequently analyzed by LC/MS/MS. Calibration curves were linear from 1 to 500 nmol/l for imatinib and from 2 to 500 nmol/l for CGP 74588, with correlation coefficients (r(2)) better than 0.998 and 0.996, respectively. The limit of quantitation (LOQ) was 1 nmol/l for imatinib and 2 nmol/l for CGP 74588. Our method has been successfully applied to the determination of intracellular levels of imatinib in sensitive K562 and their resistant variant, K562/Dox cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12027124
003      
CZ-PrNML
005      
20160417111903.0
007      
ta
008      
120816s2011 enk f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.talanta.2010.11.028 $2 doi
035    __
$a (PubMed)21238737
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Mlejnek, Petr, $d 1963- $7 xx0023808 $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic. mlejnek petr@volny.cz
245    12
$a A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells / $c P. Mlejnek, O. Novak, P. Dolezel
520    9_
$a Multidrug resistance (MDR) is often associated with overexpression of the P-glycoprotein (P-gp, ABCB1). It was demonstrated that the P-gp mediated efflux decreases the drug concentration in cancer cells which results in the failure of chemotherapy. However, the MDR phenotype in cancer cells obviously involves various mechanisms. Therefore, if we want to estimate a contribution of the P-gp expression to the MDR phenotype, a clear quantitative relationship between the intracellular drug level and cell sensitivity must be established. To achieve this goal, a sensitive and non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite N-desmethyl imatinib (CGP 74588) has been developed. The assay is based on an optimised extraction of cells with 4% formic acid after their separation from the growth medium by centrifugation through a layer of silicone oil. Cell extracts are subsequently analyzed by LC/MS/MS. Calibration curves were linear from 1 to 500 nmol/l for imatinib and from 2 to 500 nmol/l for CGP 74588, with correlation coefficients (r(2)) better than 0.998 and 0.996, respectively. The limit of quantitation (LOQ) was 1 nmol/l for imatinib and 2 nmol/l for CGP 74588. Our method has been successfully applied to the determination of intracellular levels of imatinib in sensitive K562 and their resistant variant, K562/Dox cells.
650    _2
$a protinádorové látky $x chemie $x metabolismus $7 D000970
650    _2
$a biotest $x metody $7 D001681
650    _2
$a plynová chromatografie s hmotnostně spektrometrickou detekcí $7 D008401
650    _2
$a lidé $7 D006801
650    _2
$a buňky K562 $7 D020014
650    _2
$a chronická myeloidní leukemie $x metabolismus $7 D015464
650    _2
$a limita detekce $7 D057230
650    _2
$a piperaziny $x chemie $x metabolismus $7 D010879
650    _2
$a pyrimidiny $x chemie $x metabolismus $7 D011743
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Novák, Ondřej $7 xx0120183 $u Laboratory of Growth Regulators, Faculty of Science, Palacky University and Institute of Experimental Botany ASCR, Slechtitelu 11, CZ-78371 Olomouc, Czech Republic
700    1_
$a Doležel, Petr $7 xx0317513 $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 3, Olomouc 77515, Czech Republic
773    0_
$w MED00004484 $t Talanta $x 1873-3573 $g Roč. 83, č. 5 (2011), s. 1466-71
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21238737 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20160417111950 $b ABA008
999    __
$a ok $b bmc $g 949166 $s 784470
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 83 $c 5 $d 1466-71 $i 1873-3573 $m Talanta $n Talanta $x MED00004484
GRA    __
$a NR9482 $p MZ0
LZP    __
$b NLK122 $a Pubmed-20120816/11/02

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...